JAMA Internal Medicine : Evaluation of Association Between Gastric Acid Suppression and Risk of Intestinal Colonization With MDROs
Interview with Christina Vandenbroucke-Grauls, MD, PhD, author of Evaluation of the Association Between Gastric Acid Suppression and Risk of Intestinal Colonization With Multidrug-Resistant Microorganisms: A Systematic Review and Meta-analysis, and Todd Campbell Lee, MD MPH, author of Deprescribing Proton Pump Inhibitors: Overcoming Resistance (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - February 24, 2020 Category: General Medicine Authors: The JAMA Network Source Type: podcasts
TWiV 586: Coronavirus update: wash your hands
In this week's coverage of the coronavirus epidemic, the TWiV team discusses the fatality rate, China's initial reaction to the outbreak, conspiracy theories, how long the virus remains infectious on surfaces, and evidence for virus in the intestinal tract. Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, Rich Condit, and Brianne Download TWiV 586 (72 MB .mp3, 119 min) Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode China reacted too slowly to epidemic (NY Times) Wuhan rounds up infected (NY Times) 2019-nCoV asymptomatic transmission report flawed (Sci...
Source: This Week in Virology - MP3 Edition - February 9, 2020 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Talk Evidence - Sepsis, talc and blindsided by blinding
Welcome to the festive talk evidence, giving you a little EBM to take you into the new year. As always Duncan Jarvies is joined by Helen Macdonald (resting GP and editor at The BMJ) and Carl Heneghan (active GP, director of Oxford University ’s CEBM and editor of BMJ Evidence)*
This month:
(1.20) Carl tells us about new research on treating sepsis with steroids that might inform practice.
(4.58)Proscribing of prophylactic PPIs or H2-blockers for intensive care patients.
(11.00) Carl wonders if we can actually rule out an increased risk of ovarian cancer with the use of talc.
(17.46) Helen drops and EBM bombshell - i...
Source: The BMJ Podcast - January 22, 2020 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
Talk Evidence - Sepsis, talc and blindsided by blinding
Welcome to the festive talk evidence, giving you a little EBM to take you into the new year. As always Duncan Jarvies is joined by Helen Macdonald (resting GP and editor at The BMJ) and Carl Heneghan (active GP, director of Oxford University’s CEBM and editor of BMJ Evidence)*
This month:
(1.20) Carl tells us about new research on treating sepsis with steroids that might inform practice.
(4.58)Proscribing of prophylactic PPIs or H2-blockers for intensive care patients.
(11.00) Carl wonders if we can actually rule out an increased risk of ovarian cancer with the use of talc.
(17.46) Helen drops and EBM bombshell - is...
Source: The BMJ Podcast - January 22, 2020 Category: General Medicine Authors: BMJ Group Source Type: podcasts
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Advanced Gastric Cancer
Thomas A. Abrams Senior Physician and Assistant Professor of Medicine at Harvard Medical School tells us his<br />thoughts on KEYNOTE-62. This is investigating pembrolizumab in HER2, PD-L1 positive advanc...
Author: obr
Added: 06/25/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 25, 2019 Category: Cancer & Oncology Source Type: podcasts
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
<br />Dr. Joseph Tabernero, MD, discusses the phase 3 keynote-062 study.<br /><br />Background: KEYNOTE062 (NCT02494583) was a randomized, active controlled study of 1L P or P+C vs C in pts with PD-L1 combined po...
Author: Annual-Meeting
Added: 06/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2019 Category: Cancer & Oncology Source Type: podcasts
Updates In Esophageal & Gastric Cancers: When Dose Of Xeloda & Oxaliplatin Is Reduced In Frail Patients They Did Very Well & Had Less Toxicity
Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Updates In Esophageal & Gastric Cancers: When Dose Of Xeloda & Oxaliplatin Is Reduced In Frail Patients They Did Very Well & Had Less Toxicity.
Author: Annual-Meeting
Added: 06/04/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2019 Category: Cancer & Oncology Source Type: podcasts
Frontline KEYTRUDA In Gastroesophageal Cancer: Patients In Immunotherapy Arm Had Significantly Lower Side Effects
Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Frontline KEYTRUDA In Gastroesophageal Cancer: Patients In Immunotherapy Arm Had Significantly Lower Side Effects.
Author: Annual-Meeting
Added: 06/04/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2019 Category: Cancer & Oncology Source Type: podcasts
"Bac-Trac" -- The Discovery Files
Bacteria's use of "swim and tumble" maneuvers and chemical secretions helps them move toward food or away from poisons as they encounter obstacles, such as those found in the human gastrointestinal tract. The research, which involved an "obstacle course" of microfluidic chambers to experiment on the bacteria, holds implications for not only biology and medicine, but also robotic search and rescue tactics. (Source: The Discovery Files)
Source: The Discovery Files - May 30, 2019 Category: Science Authors: National Science Foundation Source Type: podcasts
Novel Sepsis Phenotypes, Effect of Thrombomodulin on Mortality in Sepsis-Associated Coagulopathy, Effect of Laparoscopic vs Open Distal Gastrectomy on Survival in Gastric Cancer, and more
May 28, 2019 edition of the weekly JAMA Editors' Summary (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - May 28, 2019 Category: General Medicine Authors: JAMA Network Source Type: podcasts
Could open access have unintended consequences?
An “author pays” publishing model is the only fair way to make biomedical research findings accessible to all, say David Sanders, professor of gastroenterology at Sheffield University, but James Ashton and worries that it can lead to bias in the evidence base towards commercially driven results - a s those are the researchers who can pay for open... (Source: The BMJ Podcast)
Source: The BMJ Podcast - April 19, 2019 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
Could open access have unintended consequences?
An “author pays” publishing model is the only fair way to make biomedical research findings accessible to all, say David Sanders, professor of gastroenterology at Sheffield University, but James Ashton and worries that it can lead to bias in the evidence base towards commercially driven results - a s those are the researchers who can pay for open access fees. Dave deBronkart just wants patients to have access to key research.
Read the full head to head:https://www.bmj.com/content/365/bmj.l1544 (Source: The BMJ Podcast)
Source: The BMJ Podcast - April 19, 2019 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
Could open access have unintended consequences?
An “author pays” publishing model is the only fair way to make biomedical research findings accessible to all, say David Sanders, professor of gastroenterology at Sheffield University, but James Ashton and worries that it can lead to bias in the evidence base towards commercially driven results - as those are the researchers who can pay for open access fees. Dave deBronkart just wants patients to have access to key research.
Read the full head to head:
https://www.bmj.com/content/365/bmj.l1544 (Source: The BMJ Podcast)
Source: The BMJ Podcast - April 19, 2019 Category: General Medicine Authors: BMJ Group Source Type: podcasts
